Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.
Informação da revista
Vol. 43. Núm. S3.
Páginas S56-S57 (Novembro 2021)
Vol. 43. Núm. S3.
Páginas S56-S57 (Novembro 2021)
PP 62
Open Access
THE USE OF ROMIPLOSTIM IN AN INFANT
Visitas
1134
Fatma Burçin KURTİPEK, Turan BAYHAN, Vildan ÇULHA, Neşe YARALI
Ankara City Hospital
Este item recebeu
Informação do artigo
Suplemento especial
Case report
O texto completo está disponível em PDF